| 1341 |
National Cancer Institute |
Html |
en |
Smokeless Tobacco and Cancer |
A fact sheet about the health risks associated with the use of smokeless tobacco. |
| tobacco cut size | 0.465919 |
| NCI smoking cessation | 0.353151 |
| safe level | 0.345736 |
| oral tobacco | 0.470575 |
| nicotine addiction | 0.363201 |
| Human Services | 0.340767 |
| Health State-of-the-Science conference | 0.343313 |
| U.S. Department | 0.340786 |
| tobacco-specific nitrosamines | 0.373338 |
| tobacco fertilizer | 0.451995 |
| advisory committee | 0.346137 |
| powdered tobacco | 0.462627 |
| Health Organization International | 0.342988 |
| oral cancer | 0.332186 |
| National Institutes | 0.343448 |
| Watson C. Surveillance | 0.3381 |
| Tobacco Control Monograph | 0.451686 |
| moist snuff | 0.436686 |
| precancerous white patches | 0.344838 |
| International Agency | 0.339252 |
| NCI’s Smoking | 0.334129 |
| Tobacco Research | 0.437462 |
| NCI fact sheet | 0.385333 |
| lower lip | 0.34967 |
| esophageal cancer | 0.332063 |
|
| nicotine stays | 0.353085 |
| Yes. All tobacco | 0.450832 |
| National Cancer Institute | 0.373261 |
| LiveHelp online chat | 0.341688 |
| American snuff | 0.346643 |
| polynuclear aromatic hydrocarbons | 0.347124 |
| Eastern time | 0.340428 |
| spitting tobacco | 0.470917 |
| online text chat | 0.340605 |
| polycyclic aromatic hydrocarbons | 0.346589 |
| smokeless tobacco products | 0.615213 |
| smokeless tobacco cause | 0.576883 |
| Nicotine content | 0.350271 |
| un-ionized nicotine | 0.348074 |
| Surgeon General | 0.344959 |
| smokeless tobacco | 0.995709 |
| Yes. Smokeless tobacco | 0.55885 |
| dry snuff | 0.363969 |
| noncancerous oral conditions | 0.343638 |
| NIH State-of-the-Science Panel | 0.338818 |
| tobacco cause cancer | 0.483342 |
| smoking cessation counselor | 0.38611 |
| tobacco juices | 0.469352 |
| harmful chemicals | 0.350583 |
|
CLICK HERE |
| 1351 |
National Cancer Institute |
Html |
en |
Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of osteosarcoma and malignant fibrous histiocytoma of bone. |
| high-grade osteosarcoma patients | 0.629145 |
| co-operative German-Austrian-Swiss osteosarcoma | 0.55607 |
| neoadjuvant cooperative osteosarcoma | 0.624122 |
| pediatric osteosarcoma | 0.57965 |
| locally recurrent osteosarcoma | 0.5543 |
| Primary high-grade osteosarcoma | 0.612176 |
| parosteal osteosarcoma | 0.568181 |
| conventional osteosarcoma | 0.56726 |
| High grade osteosarcoma | 0.599621 |
| cooperative osteosarcoma study | 0.792783 |
| nonmetastatic osteosarcoma | 0.60813 |
| german-austrian-swiss osteosarcoma study | 0.647756 |
| high-grade osteosarcoma | 0.738641 |
| craniofacial osteosarcoma | 0.630712 |
| conventional high-grade osteosarcoma | 0.570688 |
| patients | 0.646684 |
| radiation-associated craniofacial osteosarcoma | 0.580431 |
| European Osteosarcoma Intergroup | 0.58771 |
| osteosarcoma incidence rate | 0.594537 |
| neoadjuvant chemotherapy | 0.670909 |
| high-grade extremity osteosarcoma | 0.5876 |
| Extraskeletal osteosarcoma | 0.568579 |
| Craniofacial osteosarcoma Experience | 0.589537 |
| Group Osteosarcoma Study | 0.569569 |
| radiation-related osteosarcoma | 0.565185 |
|
| osteosarcoma skip metastases | 0.57865 |
| synchronous multifocal osteosarcoma | 0.617106 |
| Osteosarcoma Intergroup study | 0.567726 |
| et al. | 0.76197 |
| PUBMED Abstract | 0.575849 |
| unresectable high-grade osteosarcoma | 0.562489 |
| primary osteosarcoma | 0.586929 |
| periosteal osteosarcoma | 0.560798 |
| osteosarcoma study group | 0.793978 |
| recurrent osteosarcoma | 0.571668 |
| non-metastatic osteosarcoma | 0.633808 |
| multi-institutional osteosarcoma study | 0.604239 |
| extremity osteosarcoma | 0.634474 |
| metastatic osteosarcoma | 0.602383 |
| multiinstitutional osteosarcoma study | 0.587612 |
| Abstract | 0.808529 |
| Clin Oncol | 0.842874 |
| operable osteosarcoma | 0.589711 |
| cooperative german-austrian-swiss osteosarcoma | 0.615008 |
| primary tumor | 0.561916 |
| intermediate-grade osteosarcoma | 0.59029 |
| Oncology Group | 0.566747 |
| cancer | 0.596697 |
| osteosarcoma | 0.959056 |
|
CLICK HERE |
| 1499 |
National Cancer Institute |
Html |
en |
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of paranasal sinus and nasal cavity cancer. |
| hemiparanasal sinus | 0.501642 |
| cure rates | 0.493854 |
| positive nodes | 0.488668 |
| standard treatment schedules | 0.549584 |
| Nodal involvement | 0.497639 |
| cancer deaths | 0.490757 |
| small percentage | 0.485324 |
| paranasal sinuses | 0.76526 |
| operable tumors | 0.521562 |
| PDQ cancer information | 0.674275 |
| (es). | 0.507032 |
| T1 mucosal carcinomas | 0.579667 |
| neck radiation therapy | 0.604078 |
| cancer information summary | 0.645943 |
| frequent type | 0.494315 |
| high doses | 0.481624 |
| Squamous cell carcinoma | 0.582109 |
| breast cancer prevention | 0.543533 |
| direct extension | 0.48751 |
| malignant degeneration | 0.512598 |
| advanced carcinomas | 0.493525 |
| ethmoid sinuses | 0.558752 |
| NCI’s PDQ | 0.512104 |
| NCI PDQ cancer | 0.582736 |
| paranasal sinus cancers | 0.63814 |
|
| radical surgery | 0.487234 |
| frontal sinuses | 0.560784 |
| radiation therapy | 0.931486 |
| low-grade benign tumor | 0.581394 |
| maxillary sinus | 0.511122 |
| locoregional recurrence accounts | 0.563108 |
| nasal vestibule | 0.506572 |
| Lymph nodes | 0.492664 |
| vital areas | 0.483188 |
| distant metastases | 0.516432 |
| bony confines | 0.499241 |
| malignant tumor | 0.600994 |
| PDQ documents | 0.510902 |
| early tumors | 0.514544 |
| radical radiation therapy | 0.591316 |
| advanced disease | 0.493565 |
| nasal cavity | 0.593061 |
| treatment volume | 0.481814 |
| local disease | 0.484616 |
| tumors | 0.539577 |
| stage III tumors | 0.513203 |
| neck cancer | 0.495811 |
| postoperative radiation therapy | 0.591777 |
| adjacent structures. | 0.488857 |
|
CLICK HERE |
| 1599 |
National Cancer Institute |
Html |
en |
Selected Vegetables/Sun's Soup (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of selected vegetables/Sun's soup as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| General Information section | 0.439986 |
| phase I/II | 0.372901 |
| soup | 0.641588 |
| eligible patients | 0.381172 |
| United States | 0.398891 |
| Human/Clinical Studies section | 0.504014 |
| standard laboratory chow | 0.498456 |
| advanced non-small cell | 0.617549 |
| toxicity arm | 0.381025 |
| control group | 0.47167 |
| Sun’s Soup | 0.39938 |
| cell lung cancer. | 0.443882 |
| Soup treatment group. | 0.419226 |
| fed standard laboratory | 0.408383 |
| conventional therapy | 0.380328 |
| Vegetables/Sun’s Soup | 0.633353 |
| dietary supplements | 0.390642 |
| tumor growth | 0.410892 |
| percent body-weight loss | 0.372171 |
| lymph node metastasis | 0.373015 |
| average KPS score | 0.387592 |
| barbat skullcap | 0.397578 |
| cancer information summary | 0.38735 |
| patent document | 0.416332 |
|
| clinical trial | 0.401308 |
| mung bean | 0.484404 |
| barbata D. Don | 0.434127 |
| best supportive care | 0.383219 |
| shiitake mushroom | 0.46504 |
| patients | 0.656235 |
| primary tumor | 0.381698 |
| Selected Vegetables/Sun | 0.926979 |
| Scutellaria barbata D. | 0.437829 |
| KPS score | 0.444385 |
| non-small cell lung | 0.820617 |
| survival arm | 0.438189 |
| Phaseolus radiatus L. | 0.435744 |
| nonconsecutive case series | 0.385568 |
| median survival time | 0.500228 |
| cell lung cancer | 0.65934 |
| study entry | 0.475867 |
| Soup treatment group | 0.54526 |
| radiation therapy | 0.522928 |
| Hedyotis diffusa Willd. | 0.437904 |
| mice fed standard | 0.407302 |
| Soup dietary supplement | 0.400111 |
| I/II clinical trial | 0.398282 |
|
CLICK HERE |
| 1617 |
National Cancer Institute |
Html |
en |
Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms. |
| red blood cells | 0.746761 |
| chronic idiopathic myelofibrosis | 0.40092 |
| cancer treatment | 0.416363 |
| primary myelofibrosis | 0.53957 |
| PDQ cancer information | 0.430215 |
| bone marrow aspiration | 0.385705 |
| clinical trial search | 0.421224 |
| white blood cells | 0.676519 |
| chronic eosinophilic leukemia | 0.451961 |
| blood cells increases | 0.444984 |
| clinical trials | 0.768861 |
| chronic neutrophilic leukemia | 0.40279 |
| mature blood cells | 0.434847 |
| fewer blood cells | 0.406923 |
| cancer information summary | 0.401424 |
| clinical trial | 0.500574 |
| early signs | 0.377313 |
| patients | 0.431687 |
| blood cells | 0.902472 |
| blood vessels | 0.37721 |
| chronic myelogenous leukemia | 0.406738 |
| Treatment Editorial Board | 0.377482 |
| essential thrombocythemia | 0.420345 |
| treatment | 0.55278 |
| stored stem cells | 0.37624 |
|
| immature blood cells | 0.399031 |
| blood stem cell | 0.37725 |
| cancer cells | 0.408902 |
| -fighting blood cells | 0.405086 |
| lymphoid stem cell | 0.374191 |
| specific cancer cells | 0.392312 |
| chronic myeloproliferative neoplasms | 0.69658 |
| signs | 0.38226 |
| polycythemia vera | 0.418683 |
| patient | 0.388228 |
| treatment clinical trials | 0.396123 |
| blood stem cells | 0.497004 |
| National Cancer Institute | 0.457233 |
| routine blood test | 0.45249 |
| new treatment | 0.393316 |
| white blood cell | 0.399685 |
| extra blood cells | 0.469808 |
| bone marrow | 0.605562 |
| PDQ summary | 0.382577 |
| cancer clinical trials | 0.425229 |
| blood clots | 0.392843 |
| cancer | 0.517448 |
| information | 0.439199 |
| Myelogenous Leukemia Treatment | 0.387746 |
|
CLICK HERE |
| 1694 |
National Cancer Institute |
Html |
en |
Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version |
Childhood central nervous system (CNS) germ cell tumors form from germ cells (a type of cell that forms as a fetus develops and later becomes sperm in the testicles or eggs in the ovaries). Learn about the signs, tests to diagnose, and treatment of pediatric germ cell tumors in the brain in this expert-reviewed summary. |
| tumor marker levels | 0.3628 |
| cancer treatment | 0.421684 |
| Cell Tumors Treatment | 0.421872 |
| tumor marker | 0.418943 |
| blood tumor marker | 0.368072 |
| tumor marker tests | 0.401497 |
| germ cell tumor | 0.574325 |
| chemotherapy | 0.377281 |
| following PDQ summaries | 0.365055 |
| PDQ cancer information | 0.426073 |
| clinical trials | 0.64034 |
| Pediatric Treatment Editorial | 0.365107 |
| cancer information summary | 0.398144 |
| clinical trial | 0.507274 |
| childhood cns | 0.519486 |
| tumor markers | 0.382879 |
| CNS germ cell | 0.581589 |
| Extracranial Germ Cell | 0.410121 |
| different types | 0.371541 |
| NCI PDQ cancer | 0.369493 |
| radiation therapy | 0.586685 |
| Treatment Editorial Board | 0.36802 |
| Cord Tumors Treatment | 0.393052 |
| late effects | 0.370411 |
| treatment | 0.581174 |
|
| cancer cells | 0.438925 |
| treatment clinical trial | 0.368062 |
| PDQ Pediatric Treatment | 0.363419 |
| nervous system germ | 0.412082 |
| treatment clinical trials | 0.389618 |
| National Cancer Institute | 0.397655 |
| diagnose childhood CNS | 0.382168 |
| spinal cord | 0.499499 |
| tumor cells | 0.386305 |
| Germ cells tumors | 0.441556 |
| new treatment | 0.423148 |
| high tumor marker | 0.363373 |
| childhood cancer information | 0.366666 |
| external radiation therapy | 0.366121 |
| brain | 0.390174 |
| PDQ summary | 0.396735 |
| germ cell tumors | 0.941151 |
| cells | 0.445231 |
| cancer clinical trials | 0.367524 |
| stem cell rescue | 0.36994 |
| cancer | 0.582086 |
| standard treatment | 0.367712 |
| tumor marker level | 0.399336 |
| spinal cord tumors | 0.390737 |
|
CLICK HERE |
| 2050 |
National Cancer Institute |
Html |
es |
Análisis del antígeno prostático específico (PSA) |
Hoja informativa sobre la prueba del antígeno prostático específico (PSA) y los exámenes selectivos de detección para el cáncer de próstata, y clarifica los beneficios y limitaciones de dicha prueba. |
| posibles complicaciones | 0.529476 |
| United States Preventive | 0.549836 |
| hiperplasia prostática benigna | 0.569875 |
| fusión génica tmprss2-erg | 0.5485 |
| estudio plco | 0.535774 |
| PLCO trials | 0.538088 |
| eréctil o incontinencia | 0.532144 |
| médico quizás | 0.54755 |
| ng per milliliter | 0.54786 |
| concentration-based assay | 0.526257 |
| Pauler DK | 0.526835 |
| structure-based isopsa assay | 0.54715 |
| estudio clÃnico plco | 0.561758 |
| tanta lentitud | 0.531594 |
| posibles perjuicios | 0.59922 |
| riesgos y beneficios | 0.531533 |
| Servicios Preventivos | 0.526931 |
| European Randomised Study | 0.54659 |
| hiperplasia benigna | 0.602949 |
| Preventive Health Services | 0.541802 |
| llamadas isoformas | 0.529743 |
| Screening Draft Recommendations | 0.555159 |
|
| Hugosson J | 0.571924 |
| espectro de isoformas | 0.553214 |
| Instituto Nacional | 0.525806 |
| próstata en asociación | 0.528933 |
| PSA quizás | 0.924082 |
| posibles efectos | 0.527227 |
| Internal Medicine | 0.527548 |
| Services Task Force | 0.63375 |
| among men with | 0.545229 |
| estados benignos | 0.530298 |
| agrandamiento benigno | 0.537792 |
| PubMed Abstract | 0.784346 |
| prostate cancer | 0.975142 |
| estadio inicial quizás | 0.562336 |
| obstante exámenes | 0.563732 |
| New England Journal | 0.630867 |
| Goodman PJ | 0.525307 |
| de 1 muerte | 0.528041 |
| Roobol MJ | 0.576631 |
| pequeños tumores | 0.530536 |
| Heijnsdijk EAM | 0.527351 |
| Hafron JM | 0.526062 |
|
CLICK HERE |
| 3440 |
National Cancer Institute |
Html |
es |
Exámenes de detección del neuroblastoma (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el neuroblastoma. |
| Visuals Online | 0.563675 |
| PDQ Exámenes | 0.77452 |
| Physician Data Query | 0.971175 |
| ecografÃa fetal | 0.642315 |
| prevención revisa | 0.581226 |
| graves riesgos | 0.622769 |
|
| presente sÃntomas | 0.605798 |
| información ayuda | 0.590632 |
| cuáles tipos | 0.60865 |
| National Cancer Institute | 0.613572 |
| siguientes riesgos | 0.582879 |
| Instituto Nacional | 0.71673 |
|
CLICK HERE |
| 3851 |
National Cancer Institute |
Html |
en |
Treating Cancer without Harming the Heart |
Researchers from the fields of oncology and cardiology are working to find ways to prevent, manage, and possibly even reverse the cardiovascular side effects of certain cancer therapies. |
| childhood cancers | 0.722954 |
| cardiovascular changes | 0.633513 |
| cancer treatment-related cardiotoxicity | 0.773654 |
| ischemic heart disease | 0.641571 |
| research | 0.740587 |
| task force | 0.629922 |
| childhood cancer increases | 0.668587 |
| cardiac health | 0.652664 |
| heart problems | 0.663961 |
| heart failure | 0.684862 |
| risk factors | 0.812151 |
| certain cardiac functions | 0.66508 |
| Community Oncology Research | 0.635145 |
| ischemic cardiac disease | 0.673041 |
| breast cancer patients | 0.750275 |
| adult survivors | 0.677672 |
| heart | 0.763054 |
| breast cancer trial | 0.667286 |
| Prevention Trials Research | 0.631942 |
| radiation therapy | 0.716677 |
| childhood cancer | 0.74187 |
| cancer treatments | 0.731665 |
| childhood cancer treatments | 0.686861 |
| study | 0.637136 |
|
| community oncology | 0.686779 |
| cancer treatment—chemotherapy agents | 0.673113 |
| cardiac side effects | 0.698632 |
| Anderson Cancer Center | 0.750363 |
| early cardiac dysfunction | 0.678902 |
| new research strategies | 0.65852 |
| trastuzumab-related cardiac events | 0.724465 |
| Dana-Farber Cancer Institute | 0.652906 |
| Community Oncology Cardiotoxicity | 0.640076 |
| cardiac risk factors | 0.767014 |
| subsequent research agendas | 0.636051 |
| cardiac adverse effects | 0.710556 |
| MD Anderson Cancer | 0.75179 |
| cardiac arrhythmia | 0.64223 |
| NCI Community Oncology | 0.685131 |
| NCI-supported cardiotoxicity studies | 0.649029 |
| breast cancer | 0.957268 |
| treatment-induced cardiac disease | 0.677462 |
| NCI community-based oncology | 0.638369 |
| breast cancer treatments | 0.671567 |
| Vanderbilt-Ingram Cancer Center | 0.655353 |
| cancer clinical trials | 0.814235 |
| underlying cardiovascular risk | 0.658241 |
| cardiovascular problems | 0.640023 |
|
CLICK HERE |
| 16851 |
National Cancer Institute |
Html |
es |
Sulfato de hidracina (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso del sulfato de hidracina como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Centro Nacional | 0.533358 |
| determinados efectos | 0.530508 |
| New Hampshire Avenue | 0.523784 |
| siguientes aspectos | 0.523737 |
| Drug Administration | 0.514799 |
| patients with weight | 0.533925 |
| NCI Best Case | 0.549835 |
| diagnosed non-small-cell lung | 0.536234 |
| Grosvenor M | 0.517103 |
| datos bibliográficos pubmed | 0.525622 |
| siguientes preguntas | 0.515807 |
| Heber D | 0.517667 |
| siguientes riesgos | 0.519241 |
| Instituto Nacional | 0.7207 |
| Su JQ | 0.518581 |
| Salud Complementaria | 0.556196 |
| Visuals Online | 0.516984 |
| siguientes resultados | 0.521312 |
| curso estudios | 0.529991 |
| complementarias revisa | 0.524603 |
|
| Clin Oncol | 0.521025 |
| Physician Data Query | 0.597613 |
| Goldberg RM | 0.517983 |
| PDQ Sulfato | 0.709455 |
| Estados Unidos | 0.833671 |
| Chlebowski RT | 0.553534 |
| breakdown measured | 0.519564 |
| libre uso | 0.517176 |
| compañÃa farmacéutica | 0.520309 |
| página manejo | 0.515736 |
| ¿El tratamiento | 0.532073 |
| Bulcavage L | 0.518136 |
| patients with | 0.551924 |
| siguientes datos | 0.520348 |
| ¿Los beneficios | 0.514828 |
| juntos cam | 0.514239 |
| Funcionamiento motor | 0.518326 |
| Tayek JA | 0.519355 |
| Series Program | 0.514501 |
| medicina complementaria | 0.982503 |
|
CLICK HERE |